All In Biotech

Drug Trial Radar · NCT07505303

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in Adults With Obesity

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 151 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

151

Actual

Start

Mar 23, 2026

Primary completion

Oct 15, 2026

Study completion Oct 15, 2026

Sponsor

Lead sponsor
EccogeneIndustry
Sponsor type
Industry
First posted
Apr 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

Conditions

  • Adult Obesity
  • Weight Management

Interventions

  • ECC4703Drug

    orally QD

  • PlaceboDrug

    orally QD

  • SemaglutideDrug

    SC once weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in Body Weight from Baseline (Week 9) to Week 20Time frame: Baseline (Week 9) to Week 20
  2. Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20Time frame: Baseline (Week 9) to Week 20
  3. Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic SteatosisTime frame: Baseline (Week 9) to Week 20
  4. Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic SteatosisTime frame: Baseline (Week 9) to Week 20
  5. Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFFTime frame: Baseline (Week 9) to Week 20

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Central Research Associates - Flourish - PPDS

    Birmingham, Alabama

  • Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS

    Anaheim, California

  • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS

    Los Alamitos, California

  • AES - DRS - Optimal Research Florida - Melbourne

    Melbourne, Florida

  • ForCare Clinical Research - CenExel FCR - PPDS

    Tampa, Florida

  • Atlanta Center for Medical Research - CenExel ACMR - PPDS

    Atlanta, Georgia

  • iResearch Atlanta - CenExel - PPDS

    Decatur, Georgia

  • AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis

    Richfield, Minnesota

  • Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS

    Omaha, Nebraska

  • Velocity Clinical Research - Durham - PPDS

    Durham, North Carolina

  • Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS

    Cincinnati, Ohio

  • Velocity Clinical Research - Providence - PPDS

    East Greenwich, Rhode Island

  • Velocity Clinical Research - Dallas - PPDS

    Dallas, Texas

  • AES - DRS - Synexus Clinical Research US, Inc. - San Antonio

    San Antonio, Texas

  • Flourish Research - San Antonio - PPDS

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.